Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306192 | 0.89 | ESR1 (0.51) | MEN1KMT2ANPC1ESR1ESR2 | |
| SCHEMBL13784817 | 0.89 | ESR1 (0.51) | MEN1KMT2ANPC1ESR1ESR2 | |
| SCHEMBL5051433 | 0.89 | ESR1 (0.51) | MEN1KMT2ANPC1ESR1ESR2 | |
| SCHEMBL30124970 | 0.89 | ESR1 (0.51) | MEN1KMT2ANPC1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL30542604 | 0.87 | ESR1 (0.50) | MEN1KMT2ANPC1ESR1ESR2 | |
| SCHEMBL28905012 | 0.79 | ESR1 (0.50) | MEN1KMT2ANPC1ESR1ESR2 | |
| SCHEMBL29779937 | 0.77 | PRCP (0.55) | MEN1KMT2ANPC1MAPTPRCP | |
| SCHEMBL4978935 | 0.77 | PRCP (0.55) | MEN1KMT2ANPC1MAPTPRCP | |
| SCHEMBL28464278 | 0.77 | ESR1 (0.48) | KMT2AESR1ESR2MAPTGAA | |
| SCHEMBL5638183 | 0.76 | ESR1 (0.50) | MEN1KMT2ANPC1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-9359303-B2 | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2421862-B1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2421862-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | Purdue Research Foundation (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010124005-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1192161-B1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
| EP-1192161-A2 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0845988-B1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6194423-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION | 2001-02-27 | — | — | US | disclosed |
| WO-2000078765-A2 | CHROMENO[4,3,2-de]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5959110-A | SUBSTITUTED TETRAHYDRO-1H-NAPH(1,2,3-DE)ISOQUINOLINE COMPOUND USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0845988-A4 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0845988-A1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997006799-A1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | MEN1 3906/4885KMT2A 2426/4885NPC1 1439/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | MEN1 4494/4885KMT2A 3199/4885NPC1 1546/4885 |
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | DBH, SLC6A3, SLC18A2 | MEN1 4627/4885KMT2A 1909/4885NPC1 1945/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | MEN1 3893/4885KMT2A 2468/4885NPC1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.